Comparison of COPD exacerbator classification systems (GOLD E vs Frequent Exacerbator) using proteomics and metabolomics to identify biological differences and biomarkers.
Whole-genome cfDNA profiling identifies molecular clusters and pathways associated with oxidative damage and airflow limitation in COPD patients.
Conoce el estudio 3P que analiza los factores que predicen la progresión de la pre-EPOC a EPOC en fumadores con espirometría normal.
Study identifies 10-metabolite panel distinguishing COPD from healthy subjects with ~90% accuracy, highlighting lipid metabolism dysregulation and offering new diagnostic insights.
Proteomic Predictors of Mortality in Stable COPD is the objective of this pilot study. It searchs to identify proteomic markers and specific multiprotein signatures that could be useful in predicting long-term mortality
